XOMA (XOMA) Tops Q4 Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
RBC Capita Affirms XOMA (XOMA) at 'Sector Perform'; Gevokizumab Sale Could Bring in More non-Dilutive Cash
March 10, 2016 7:41 AM ESTRBC Capita affirms XOMA Corporation (Nasdaq: XOMA) with a Sector Perform rating and $2 price target following Q4 results and update issued Wednesday night:
Analyst Adnan Butt commented: Focus now is earlier stage endocrine programs with enough cash at hand through proof of... More
